Navigation Links
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
Date:1/12/2009

idates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.

Forward Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' late stage clinical programs. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the failure to obtain clearance of the collaboration agreement with AstraZeneca under the Hart-Scott-Rodino Act, the enrollment, conduct, completion and reporting of clinical trials, as well as risks related to the failure to achieve favorable clinical outcomes or to have the company's product candidates approved for commercial use by the U.S. Food and Drug Administration. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines and ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Americas inorganic refrigerants market, ... , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic refrigerants ...
(Date:10/22/2014)... Columbia, Md. (PRWEB) October 21, 2014 ... package, an LC/MS/MS data tool for the pain management ... efficiency of data processing and review by allowing users ... importance to clinicians. , QuantAnalytics allows analysts to ... orders. This expedites data processing by eliminating the need ...
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... 2011 During a ,Day of Science, more than 30 ... what it was like to be scientists for a day ... Inc. (S2S). The "A Day in the Life of a ... programs offered by S2S that seeks to address the fact ...
... (Nasdaq: DNDN ) today announced that management will present ... in New York City, NY on May 25, 2011 at 1:00 ... Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT ... available for replay from Dendreon,s website, www.dendreon.com .  If you ...
... BRISBANE, Calif., May 19, 2011 InterMune, Inc. (NASDAQ: ... of its 2011 Analyst Day presentations on Thursday, May ... in New York.  Presentations by InterMune,s executive management team ... and a comprehensive update of InterMune,s commercial and scientific ...
Cached Biology Technology:Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students 2Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students 3InterMune to Webcast 2011 Analyst Day Presentations 2
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... differences seen among patients with schizophrenia may be explained by ... risk genes. These findings appear in a new imaging-genetics study ... The study revealed that people with schizophrenia who had ... to develop the illness at a younger age and had ...
... like a bomb shelter, Perry Gerakines makes something ordinary yet truly ... No, this ice needs such intense cold and low pressure to ... Earth. And when Gerakines makes the ice, he must keep the ... pollen. These ultrathin layers turn out to be perfect for ...
... cells during puberty to help navigate the complex social world ... current issue of the Proceedings of the National Academy ... cells you,re born with are all you get. After studies ... wisdom held that such growth was limited to two brain ...
Cached Biology News:Single gene might explain dramatic differences among people with schizophrenia 2NASA Goddard lab works at extreme edge of cosmic ice 2NASA Goddard lab works at extreme edge of cosmic ice 3NASA Goddard lab works at extreme edge of cosmic ice 4Brain adds cells in puberty to navigate adult world 2
... SPA Screening Assay, 5 x ... eliminate lengthy sample extraction procedures and ... 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ng/ml ... C. Category: Drug Screening & Cellular ...
...
Request Info...
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
Biology Products: